Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in China / NCT07764211
Starting soon Observational

Multimodal Cohort Study of Generalized Anxiety Disorder

NCT07764211 · tracked via the Priya Life Science China tracker
Sponsor
Shanghai Mental Health Center
Phase
Observational
Started
2026-08-01
Last updated
2026-08-13

Condition(s) studied

Generalized Anxiety Disorder (GAD)

Study summary

Generalized anxiety disorder (GAD) is a common mental health condition characterized by persistent and excessive worry that is difficult to control. It can affect sleep, daily functioning, work, and quality of life. Some individuals experience long-lasting or recurrent symptoms, but the factors that influence the course and outcome of GAD are still not fully understood.

The main purpose of this study is to establish a long-term cohort of people with GAD and to better understand how their symptoms and health change over time. The study will also explore factors that may help predict symptom improvement, recurrence, and treatment outcomes.

Approximately 400 adults with GAD who receive care at Shanghai Mental Health Center will participate in this study. Participants will undergo regular clinical assessments and follow-up visits.

During the study, researchers will collect information about participants' symptoms, medical and treatment history, blood samples, and brain-related measurements. Participants will be followed at several time points to observe changes in symptoms and health. The information collected will be used to better understand the course of GAD and to support the development of more individualized approaches to diagnosis, treatment, and long-term care.

Eligibility

Sex
ALL
Min age
18 Years
Max age
65 Years
Healthy volunteers
No
Inclusion Criteria: Meets the ICD-10 diagnostic criteria for generalized anxiety disorder (GAD). Aged 18 to 65 years. Hamilton Anxiety Rating Scale (HAMA) total score \>14. Has at least a junior high school education and is able to complete self-report questionnaires. Voluntarily agrees to participate in the study and provides written informed consent. Exclusion Criteria: Meets ICD-10 diagnostic criteria for any psychiatric disorder other than GAD, as assessed using the Mini International Neuropsychiatric Interview (M.I.N.I.). Has significant suicidal ideation or is considered to be at high risk of suicide. Has a clinically significant medical condition or clinically significant laboratory abnormalities.

Primary outcome measure(s)

  • Change in Hamilton Anxiety Rating Scale (HAMA) Total Score From Baseline — Baseline; Weeks 2, 4, 8, 12, 24, 36, and 48; and 1-year extended follow-up
    The Hamilton Anxiety Rating Scale (HAMA) is a clinician-rated scale used to assess the severity of anxiety symptoms. The scale consists of 14 items, each rated from 0 to 4, resulting in a total score ranging from 0 to 56. Higher scores indicate greater severity of anxiety symptoms. Changes in HAMA total scores from baseline will be assessed during follow-up.

Trial sites (1)

FacilityCityRegionStatus
Shanghai Mental Health Center Shanghai China

More Shanghai Mental Health Center trials in China

A Study to Evaluate the Effectiveness of Group Gaming Interventions for Individuals With Problematic Gaming Behavior and Gaming Disorder. Recruiting
Home-Based Wearable rTMS Therapy for Moderate to Severe Depression Starting soon
Cerebellum-Prefrontal Paired-Pulse Stimulation for Methamphetamine Use Disorder Recruiting
A Study for the Disrupted Interpersonal Interaction Among Gaming Disorder Individuals and Treatment Recruiting
Efficacy and Influencing Factors of Mindfulness-Based Exposure Group Therapy for OCD Recruiting

Other trials for the same condition

Transcranial Alternating Current Stimulation to Enhance Mindfulness Therapy in Generalized Anxiety Disorder Starting soon
Acupuncture for Generalized Anxiety Disorder Starting soon
Temporal Interference Transcranial Alternating Current Stimulation Targeting the BNST or Amygdala for Generalized Anxiety Disorder Starting soon
Clinical Efficacy and Mechanism of rTMS Based on dlPFC in the Intervention of Generalized Anxiety Disorder With Insomnia Enrolling by invitation
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07764211 on ClinicalTrials.gov ↗ ← All trials in China